Stock AXIM AXIM BIOTECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials AXIM Biotechnologies, Inc.

Equities

AXIM

US05463V1008

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 12:16:52 2024-05-02 EDT 		5-day change 1st Jan Change
0.0122 USD -18.67% Intraday chart for AXIM Biotechnologies, Inc. +11.93% -35.79%
04-16 AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-15 AXIM Biotechnologies, Inc. announced that it has received $0.814555 million in funding CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 44.57 23.01 54.19 59.71 5.164 4.515
Enterprise Value (EV) 1 50.57 29.93 60.07 66.01 10.81 10.25
P/E ratio -6.36 x -3.51 x -7.09 x -3.55 x -0.69 x -0.48 x
Yield - - - - - -
Capitalization / Revenue 228 x 28.8 x - 988 x 582 x 114 x
EV / Revenue 259 x 37.4 x - 1,092 x 1,218 x 259 x
EV / EBITDA -10 x -4.6 x -12.2 x -11.2 x -2.56 x -4.41 x
EV / FCF -22.6 x -10.3 x -25.6 x 129 x 22.7 x 10.6 x
FCF Yield -4.43% -9.73% -3.91% 0.78% 4.4% 9.42%
Price to Book -7.35 x -3.5 x 34.6 x -25.6 x -1.1 x -0.61 x
Nbr of stocks (in thousands) 59,433 63,035 125,197 137,904 186,442 237,649
Reference price 2 0.7500 0.3650 0.4328 0.4330 0.0277 0.0190
Announcement Date 19-04-08 20-05-14 21-04-15 22-04-15 23-04-17 24-04-16
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.1956 0.7995 - 0.0605 0.008875 0.0395
EBITDA 1 -5.033 -6.502 -4.933 -5.893 -4.227 -2.324
EBIT 1 -5.036 -6.506 -4.949 -8.009 -4.653 -2.751
Operating Margin -2,574.53% -813.73% - -13,246.02% -52,425.6% -6,960.98%
Earnings before Tax (EBT) 1 -6.755 -6.448 -6.291 -16.02 -6.243 -8.06
Net income 1 -6.755 -6.448 -6.41 -16.03 -6.243 -8.06
Net margin -3,453.05% -806.47% - -26,517.21% -70,343.09% -20,394.96%
EPS 2 -0.1179 -0.1041 -0.0611 -0.1219 -0.0400 -0.0400
Free Cash Flow 1 -2.242 -2.913 -2.346 0.5119 0.476 0.9661
FCF margin -1,146.04% -364.33% - 846.66% 5,362.95% 2,444.81%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 19-04-08 20-05-14 21-04-15 22-04-15 23-04-17 24-04-16
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 6 6.92 5.88 6.3 5.64 5.74
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -1.192 x -1.064 x -1.192 x -1.069 x -1.335 x -2.469 x
Free Cash Flow 1 -2.24 -2.91 -2.35 0.51 0.48 0.97
ROE (net income / shareholders' equity) 109% 100% 242% 4,149% 174% 129%
ROA (Net income/ Total Assets) -147% -215% -47.6% -60.2% -61% -41.3%
Assets 1 4.594 2.998 13.48 26.65 10.24 19.53
Book Value Per Share 2 -0.1000 -0.1000 0.0100 -0.0200 -0.0300 -0.0300
Cash Flow per Share 2 0.0300 0.0100 0 0 0 0
Capex - - 0.1 0.04 0.01 -
Capex / Sales - - - 66.98% 98.14% -
Announcement Date 19-04-08 20-05-14 21-04-15 22-04-15 23-04-17 24-04-16
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
AXIM BIOTECHNOLOGIES, INC. Stock AXIM Biotechnologies, Inc.
-35.79% 4.18M
MODERNA, INC. Stock Moderna, Inc.
+22.26% 42.68B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.57% 42.4B
LONZA GROUP AG Stock Lonza Group AG
+45.32% 40.04B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.08% 24.94B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.05% 18.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.00% 12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.83% 11.95B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.64% 11.55B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AXIM Stock
  4. Financials AXIM Biotechnologies, Inc.